|
|
|
|
Vol. 60, Issue 5, 999-1007, November 2001
-Adrenergic Ligands with Distinct Inverse Efficacies
Département de Biochimie and le Groupe de Recherches sur le Système Nerveux Autonome, Université de Montréal, Montréal, Québec, Canada
| |
Abstract |
|---|
|
|
|---|
Allosteric models of G protein-coupled receptors predict that G protein
influences the spontaneous isomerization between inactive (R) and
active (R*) conformations. Since inverse agonists have been proposed to
preferentially bind to the inactive and uncoupled form(s), changes in
the G protein content should influence the binding properties of these
ligands. To test this hypothesis, we systematically assessed the effect
of G proteins on the binding of
2-adrenergic ligands
with distinct levels of inverse efficacy. Recombinant baculoviruses
encoding the human
2-adrenoreceptor (
2AR)
were expressed alone or in combination with G protein subunits in Sf9
cells. Coexpression with the G protein
s
1
2 did not influence the relative efficacy of the ligands to inhibit the adenylyl cyclase but induced considerable decrease in number of sites detected by
[3H]ICI 118551, [3H]propranolol, and
125I-cyanopindolol. This loss was proportional to the
inverse efficacy of the ligand used as the radiotracer in the assay.
The addition of Gpp(NH)p inhibited the effects of G protein
overexpression indicating that the G proteins acted allosterically.
Consistent with this notion, Western blot analysis revealed that
coexpression with the G proteins was not accompanied by a loss of
immunoreactive
2AR. Such allosteric effects of the G
proteins were also observed in mammalian cells expressing endogenous
level of G proteins indicating that the phenomenon is not unique to
overexpression systems. Taken together, these results demonstrate that
the apparent receptor number detected by radiolabeled inverse agonists
is affected by the content in G proteins as a result of their influence
on R/R* isomerization.
| |
Introduction |
|---|
|
|
|---|
Traditionally,
G protein-coupled receptors (GPCR) were considered to rest in an
inactive conformation under basal conditions, requiring the presence of
an agonist to undergo the necessary changes leading to activation and
therefore receptor/G protein coupling. In this occupational
interpretation of receptor activation, antagonists were believed to
lack intrinsic activity, occupying the receptor without inducing
changes in G protein coupling. More recently, a growing body of
evidence has challenged this notion. Indeed, following the development
of receptor mutants that show constitutive (ligand-independent)
activity and that of overexpression systems that revealed spontaneous
agonist-independent activity even for wild-type GPCRs, the notion that
some ligands (inverse agonists) may inhibit constitutive/spontaneous
activity has emerged (for review, see Kenakin, 1996
; Bond and Bouvier,
1998
). As traditionally described for agonists, inverse agonists were
also found to display different efficacies, ranging from almost neutral
antagonism to full inverse agonism (Chidiac et al., 1994
; Leeb-Lundberg
et al., 1994
; Labrecque et al., 1995
; Gardella et al., 1996
; Mullaney et al., 1996
; Smith et al., 1996
; Lee et al., 1997
; Jansson et al.,
1998
). Based on the interpretation of these studies, numerous thermodynamic models proposing the allosteric interconversion of
receptors between active and inactive states have been proposed (Samama
et al., 1993
; Kenakin, 1995
; Weiss et al., 1996
; Leff and Scaramellini,
1998
).
According to the two-state model (Karlin, 1967
; Colquhoun, 1973
; Thron,
1973
; Leff, 1995
), agonist-independent activation of GPCRs is believed
to reflect the spontaneous isomerization of the receptor between
inactive (R) and active (R*) conformations, with the equilibrium under
native conditions shifted toward R for most receptors. In this model,
agonists are considered as preferentially binding and stabilizing R*
(thus leading to activation) whereas inverse agonists by binding to R
would inhibit the system. Neutral antagonists that do not
discriminate between the two conformers would leave the equilibrium
between the two isomers unchanged. Furthermore, receptors are known to
interact with a transducer G protein and thus to exist in an uncoupled
(R) and a coupled (RG) conformation. Based on the thermodynamic
description of the ternary complex model and its extended form (De Lean
et al., 1980
; Lefkowitz et al., 1993
; Samama et al., 1993
), R* would
spontaneously couple to the G protein whereas the interaction between
inactive R and G would not be favored. Furthermore, the activated R*
state has been shown to be stabilized by the guanine nucleotide-free G
protein
-subunit (Seifert et al., 1998
), and it is this
activated/coupled form (R*G) of the receptor that displays the highest
affinity for agonists. On the other hand, GTP analogs are considered to decrease the affinity of agonists for their cognate receptors by
promoting receptor/G protein dissociation (De Lean et al., 1980
;
Kenakin, 1996
).
In keeping with the prediction of the two-state allosteric model, it is
expected that any condition that would change the equilibrium between R
and R* must have an impact on receptor activity and ligand affinity
simultaneously. In keeping with this prediction, it has been shown for
many GPCRs that an increase in constitutive activity is linked to an
increase in apparent agonist affinity (Cotecchia et al., 1990
;
Kjelsberg et al., 1992
; Ren et al., 1993
; Samama et al., 1993
) and that
such increases in binding affinity correlate well with the
pharmacological efficacy of agonists (Samama et al., 1993
). On the
other hand, if as predicted by the two-state model, inverse agonists
bind preferentially to the inactive form of the receptor, the apparent
affinity of these drugs is expected to decrease in conditions that
shift the equilibrium toward R* (Gether and Kobilka, 1998
). Although
changes in inverse agonist binding have been reported in some studies
in which R/R* or R/RG equilibrium was manipulated (Barker et al., 1994
;
Bouaboula et al., 1997
; Francken et al., 2000
), no study has
systematically examined the prediction of the two-state model on
inverse agonist binding properties.
The aim of the present study was to directly assess the effect of
promoting R*G formation on inverse agonist binding. For this purpose,
we took advantage of the baculovirus/Spodoptera frugiperda 9 (Sf9) cell expression system, which has extensively been used to
reconstitute the interactions between specific GPCRs and their cognate
G proteins (Butkerait et al., 1995
; Grunewald et al., 1996
; Barr and
Manning, 1997
; Barr et al., 1997
; Francken et al., 2000
).
Overexpression of G
s
1
2 led to a significant reduction of
inverse agonist binding to the human
2AR
expressed in the same cells. In conformity with the two-state model,
the extent of the changes in inverse agonist binding was proportional to inverse efficacy of the ligands tested. Similar binding decreases were also observed when a constitutively active
2AR mutant was used, indicating that
stabilization of R* through either constitutively activating mutation
or overexpression of G protein has similar effects on inverse agonist
binding properties.
| |
Materials and Methods |
|---|
|
|
|---|
Baculoviruses.
The recombinant c-myc
2AR human baculoviruses was constructed by
Mouillac et al. (1992)
. Recombinant baculoviruses encoding the
different G protein subunits (rat
s short form, rat
i1, human
q, bovine
1, bovine
2) and
-galactosidase were obtained from Biosignal (Montréal,
Québec). Those encoding the constitutively active mutant
2AR were kindly provided by Dr. B. K. Kobilka (HHMI, Stanford University Medical School, CA).
Cell Culture and Baculovirus Infection.
Sf9 cells were
cultured as monolayers in T flasks as described previously (Chidiac et
al., 1996
). Cells (at a density of 1-2 × 106 cells/ml) were infected with c-myc
2AR or constitutively active mutant
2AR encoding baculovirus at a multiplicity of
infection (m.o.i.) of 1. For the coexpression of multiple G
- (G
s,
G
i1, and G
q), G
1-, and G
2-subunits, an m.o.i. of 2 was used
for each virus. The total m.o.i. was maintained at 8 in all infections by using the appropriate amount of
-galactosidase virus. At 48-h postinfection, cells were harvested by centrifugation, washed twice
with ice-cold phosphate-buffered saline (PBS), and directly used for
membrane preparation. HEK293s cells stably expressing the
2AR were grown as monolayers in Dulbecco's
modified Eagle's medium supplemented with 10% fetal bovine serum, 1 mM glutamine, 500 units/ml penicillin, and 500 units/ml streptomycin.
Membrane Preparation.
Cells were resuspended and lysed under
hypotonic conditions (5 mM Tris-HCl, pH 7.4, 2 mM EDTA, 5 µg/ml
leupeptine, 5 µg/ml soybean trypsin inhibitor, and 10 µg/ml
benzamidine) and homogenized with a polytron homogenizer (Ultra-Turrax;
Janke and Kunkel, Staufen, Germany) for 5 s. Homogenates were
centrifuged at 500g for 5 min at 4°C, and the resulting
supernatant fraction was centrifuged at 25,000g for 20 min
at 4°C. The membrane pellets were washed twice in the same buffer and
centrifuged under the same conditions. The membrane pellet was finally
resuspended in 75 mM Tris-HCl, pH 7.4, containing 5 mM
MgCl2, 2 mM EDTA, and protease inhibitors as in
the lysis buffer. The membranes were immediately used for adenylyl
cyclase activity and radioligand binding assay or frozen at
80°C
for Western blot analysis. Protein content in membrane preparation was
estimated with the Bradford protein assay (Bradford, 1976
) using the
Bio-Rad kit. Bovine serum albumin was used as a standard.
Adenylyl Cyclase Activity.
Membrane adenylyl cyclase
activity was performed according to the method of Salomon et al.
(1974)
. Briefly, 5 µg of membrane protein was incubated in the
absence or presence of various concentrations of
2AR ligands with 0.12 mM ATP,
106 cpm
[
-32P]ATP/assay (NEN Mandel), 0.1 mM
cAMP, 53 µM GTP, 2.7 mM phosphoenolpyruvate, 0.1 mM
isobutylmethylxanthine, 1 unit of myokinase, and 0.2 unit of pyruvate
kinase, in a total volume of 50 µl. The samples were incubated at
37°C for 15 min, and the reaction was stopped by addition of 1 ml of
a cold solution containing 0.4 mM ATP, 0.3 mM cAMP, and
[3H]cAMP (25,000 cpm). cAMP was isolated by
sequential chromatography using a Dowex gel followed by aluminum oxide.
Radioligand Binding Assay.
Radioligand binding assays were
performed essentially as described previously (Chidiac et al., 1996
).
Briefly, 1 to 3 µg of membrane proteins were incubated in a total
volume of 0.5 ml in a buffer containing 75 mM Tris-HCl, pH 7.4, 5 mM
MgCl2, 2 mM EDTA, protease inhibitors, and
varying concentrations of the different radioligands tested:
125I-cyanopindolol (NEN Mandel),
[3H]propranolol (NEN Mandel), or
[3H]ICI 118551 (Tocris Cookson, St. Louis, MO).
For single-point binding analysis, saturating concentrations of each
ligand were used: 250 pM, 6 nM, and 8 nM for
125I-cyanopindolol,
[3H]propranolol, and
[3H]ICI 118551, respectively. Nonspecific
binding was estimated in the presence of 10 µM alprenolol (Sigma, St.
Louis, MO). Binding reactions were incubated at room temperature for 60 min for [3H]propranolol and 90 min for
125I-cyanopindolol and
[3H]ICI 118551 and were terminated by rapid
filtration through glass fiber (GF/C) filters (Whatman, Maidstone, UK)
with ice-cold 25 mM Tris-HCl, pH 7.4. The experiments with Gpp(NH)p
were performed with a concentration of 100 µM in the binding assay.
Western Blot Analysis.
Membranes from Sf9 cells
expressing the
2AR and different G protein
subunits were reduced in Laemmli's sample buffer (Laemmli, 1970
) and 5 and 10 µg of proteins were subjected to SDS-polyacrylamide gel
electrophoresis (PAGE). Proteins were then transferred to nitrocellulose membrane (Xymotech) and probed for 1 h at
room temperature with a mouse anti-c-myc monoclonal antibody
(9E10, 1:2,000), a rabbit anti-
2AR polyclonal
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA; 1:10,000),
and rabbit anti-Gs, Gi, or Gq polyclonal antibodies (Santa Cruz
Biotechnology, Inc.; 1:5,000). The first antibody was revealed with a
horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG
(Amersham Pharmacia Biotech, Piscataway, NJ; 1:20,000) and
chemiluminescence using Renaissance plus kit (NEN Mandel). To ensure
that the intensity of the signal was directly proportional to the
amount of receptor protein loaded, serial dilutions of each membrane
preparation were analyzed.
Flow Cytometry.
The flow cytometry was performed as
previously described (Morello et al., 2000
). Briefly, Sf9 cells were
permeabilized in PBS containing 0.15% Triton, fixed with 3%
paraformaldehyde, and subsequently incubated with
anti-
2AR (Santa Cruz Biotechnology, Inc.)
antibody for 1 h at room temperature. The cells were then washed
with PBS and incubated with phycoerythrin-conjugated goat anti-rabbit
antibody (Immunotech, Westbrook, ME) for 1 h at room temperature.
The cells were washed in PBS and analyzed on a FACS caliber
Becton-Dickson flow cytometer (BD Immunocytometry Systems, San Jose,
CA) set up to detect phycoerythrin fluorescence (585 ± 21 nm).
For each sample, 10,000 cells were analyzed.
Data Analysis.
For adenylyl cyclase assay, the data were
calculated as picomoles of cAMP produced per minute per milligram of
proteins and were expressed as percentage of control. Dose-response
curves and saturation experiments were analyzed by nonlinear regression using the Prism program (GraphPad Software, San Diego, CA).
EC50 values were derived from the curves. Maximal
efficacies of each drug were determined as previously defined (Chidiac
et al., 1994
). For each set of data, the efficacy of the most
inhibitory ligand, ICI 118551, was set at
1.
Bmax and Kd
values of the radioligand and IC50 values of
inhibitors were derived from the curve fitting. Statistical analyses
were performed using the Student's t test. p < 0.05 was considered statistically significant.
| |
Results |
|---|
|
|
|---|
In an effort to systematically test the hypothesis that inverse
agonists bind with higher affinity to the inactive/uncoupled forms of
the receptor (R), we assessed the influence of G protein overexpression
and constitutive activation of the
2AR in
direct radioligand binding experiments. For this purpose, the relative efficacy of commonly used
2AR radioligands was
first assessed in membranes from Sf9 cells expressing a high copy
number of the human
2AR (8.43 ± 1.76 pmol/mg of protein). As shown in Fig. 1,
ICI 118551, propranolol, and cyanopindolol were found to be inverse
agonists because they inhibited the basal adenylyl cyclase activity by
48, 34, and 23%, respectively. The level of adenylyl cyclase activity,
detected at the highest ICI 118551 concentrations, was
undistinguishable from that observed in cells that did not express the
receptor (data not shown), and thus an efficacy of
1 (full inverse
agonist) was attributed to this compound. The inverse efficacies of
cyanopindolol and propranolol were expressed relative to that of ICI
118551 (Table 1).
|
|
Coexpression of the
2AR with G
s
1
2
promoted a 2.9-fold increase in the basal adenylyl cyclase activity
(60 ± 0.6 versus 175 ± 13 pmol/mg of protein/min for
membranes from Sf9 cells expressing the
2AR
and the
2AR/G
s
1
2,respectively) but
did not influence the relative efficacy nor the potency of the three
compounds tested (Table 1).
To test the effect of G protein coupling on the binding properties of
these inverse agonists, saturation binding assays were carried out in
membranes derived from cells expressing the receptor alone or in
combination with G
s
1
2. As shown in Fig.
2 and Table 2, the
apparent affinities of 125I-cyanopindolol,
[3H]propranolol, and
[3H]ICI 118551 for the
2AR were not affected by the coexpression with
G
s
1
2, although a significant decrease in the
Bmax values was observed for the three
inverse agonists tested (Fig. 2 and Table 2). To further document this
effect of the G protein expression on the apparent binding capacity of
the receptor, a large number of binding experiments were carried out
with saturating concentration of each of the ligands. Figure
3 summarizes the results obtained in 12 to 15 independent experiments. Not only was the decrease in
Bmax promoted by the coexpression of
G
s
1
2 found to be highly reproducible, but the extent of the
reduction was proportional (r2 = 0.989) to the relative inverse efficacy of the ligand used in the
binding assay (Fig. 3B).
|
|
|
The loss in binding sites observed did not result from a reduction in
2AR protein expression since an increase
rather than a decrease in immunoreactive
2AR
was observed upon coexpression with G
s
1
2 (Fig.
4). The increase in the amount of
receptor protein detected most likely results from a stabilizing effect of the G protein. This effect cannot be attributed to a particularity of the N terminus myc epitope tag since similar results were
obtained using an anti-
2AR antibody directed
against the carboxyl tail of the receptor (Santa Cruz Biotechnology,
Inc.). Indeed, both the 45- to 55-kDa bands corresponding to
heterogeneously glycosylated monomeric forms of the receptor and the
dimeric species observed at ~120 kDa were found to be increased using
the two antibodies. The detection of a greater number of bands in the
45- to 55-kDa region when using the anti-
2AR
could be due to the fact that the myc epitope is localized
close to the N terminus glycosylation site where it may be partly
masked by the carbohydrate moieties, whereas the
anti-
2AR is directed against the C terminus of
the receptor.
|
The apparent contradiction between the loss of binding site and the increase in receptor protein suggests that only a fraction of the receptor population can bind the radioligands used in the assays. This proposition would be consistent with the idea that the increased expression of G proteins stabilizes a coupled/activated state of the receptor that has an affinity for the inverse agonists that is too low to be detected in the binding assay.
If the latter hypothesis is true, one would predict that promoting the
uncoupling of the receptor from the G protein by adding guanine
nucleotide in the binding assay would reduce the effect of the G
protein overexpression. As can be seen in Fig.
5, the addition of Gpp(NH)p in the
binding assay reduced the loss of binding sites detected with
[3H]ICI 118551, [3H]propranolol, and
125I-cyanopindolol upon coexpression of
G
s
1
2.
|
To test the specificity of the phenomenon, coexpression with another G
protein that has been shown to interact with the
2AR, Gi (Daaka et al., 1997
), and one that
does not, Gq (Offermanns and Simon, 1995
), was investigated. As for
G
s
1
2, coexpression of the receptor with
G
i1
1
2 led to a significant reduction of the number of sites that were recognized by the three inverse agonists
(Fig. 6A). In contrast, coexpression with
G
q
1
2 was without effect. Since G
q could readily be detected
by Western blot analysis (Fig. 6B), the data indicate that the effect
of G proteins on inverse agonist binding is linked to their selectivity of coupling to the receptor. However, the similar effect observed for
G
s and G
i cannot be interpreted as an equivalent affinity of the
receptor for the two G proteins since their relative level of
expression cannot be easily determined. Nevertheless, to determine whether the influence of the G proteins can be observed at
physiological level of expression, the effect of uncoupling the G
proteins from the receptor using either cholera (CTX) or pertussis
(PTX) toxins was investigated in HEK293s cells stably expressing the
2AR. As shown in Fig. 6C, a significant
increase in 125I-cyanopindolol binding capacity
was observed upon treatment with both toxins indicating that coupling
to the two G proteins occurs at endogenous level of expression and can
influence receptor binding properties.
|
In an effort to determine which of the
-subunit, the 
-dimer,
or the heterotrimer is responsible for the reduction in binding sites
detected by the inverse agonists, the number of receptors measured by
125I-cyanopindolol was assessed following
coexpression with G
s, G
1
2, or G
s
1
2. A significant
reduction was observed in the three coexpression conditions (Fig.
7). However, the greatest reduction was
seen upon coexpression with the heterotrimer, 43%, compared with 34%
and 17% for coexpression with G
s and G
1
2, respectively. Given
that exogenous G
s and G
1
2 can interact with the insect
s-like and 
-subunits, these data suggests that interaction
with the heterotrimer is most likely responsible for G protein effect
on inverse agonist binding.
|
If the assumption that the loss of inverse agonist binding sites
results from a stabilization of the activated form of the receptor by
the heterotrimeric G protein is correct, one could predict that
mutations that lead to constitutive activation of the receptor should
have similar effects. To test this hypothesis, 125I-cyanopindolol binding was assessed in cells
expressing either the wild-type or the constitutively active
2AR (CAM
2AR) in which L266, K267, H269, and L272 were replaced by S, R, K, and A that correspond to the homologous region of constitutively active
1b adrenergic receptor (Cotecchia et al., 1990
; Samama et al., 1993
). When
cells expressing identical amounts of either
2AR or CAM
2AR protein, as assessed by FACS analysis (Fig.
8A), were tested for the number of
125I-cyanopindolol binding sites, a significantly
lower number of sites were found for the
CAM
2AR (Fig. 8B). To confirm that the difference in radioligand binding did not result from a lower level of
protein expression or greater degradation, Western blot analyses were
carried out. Equivalent amounts of binding sites detected by
125I-cyanopindolol in membranes expressing the
wild-type
2AR or the
CAM
2AR were resolved by electrophoresis and
detected using an anti-
2AR antibody (Santa
Cruz Biotechnology, Inc.). As shown in Fig. 8C, the total amount of
2AR immunoreactivity was 1.5-fold higher in
membranes from Sf9 cells infected with the
CAM
2AR than those expressing the wild-type
receptor, thus confirming that a significant proportion of the
CAM
2AR is unable to bind
125I-cyanopindolol.
|
To investigate whether CAM
2AR coupling to Gs
protein could further modify inverse agonist binding, the specific
binding of 125I-cyanopindolol,
[3H]propranolol, and
[3H]ICI 118551 was assessed in membranes
derived from Sf9 cells expressing the constitutively active receptor
alone or in combination with G
s
1
2. As previously observed for
the wild-type
2AR (Fig. 3A), the number of
CAM
2AR binding sites detected by the three radioligands tested was significantly reduced upon overexpression of
G
s (Fig. 9), indicating that
interaction with the G protein can further stabilize the
CAM
2AR into a conformation that is not
recognized by the inverse agonists.
|
| |
Discussion |
|---|
|
|
|---|
The results of the present study demonstrate that overexpression
of trimeric G proteins
(G
s
1
2 or
G
i
1
2) results in a significant decrease of the total number of
2AR sites detected by inverse agonists. This
finding is consistent with two of the predictions made by allosteric
models for receptor activation (such as the extended ternary and the
cubic models): 1) inverse agonists bind preferentially to the inactive
(R) form of the receptor and 2) the interaction of the receptor with
its cognate G protein stabilize the active form (R*) at the expense of
R (Lefkowitz et al., 1993
; Samama et al., 1993
; Bond et al., 1995
;
Kenakin, 1995
; Leff, 1995
; Leff and Scaramellini, 1998
). Similarly, our observation that the extent of decrease in inverse agonist binding is
directly correlated to the inverse efficacy of the ligand used is
consistent with efficacy-related changes in ligand binding predicted by
all of these models following changes in R/R* ratio. Indeed, the
conceptual framework proposed by the latter suggests that relative
efficacy results from the distinct preferences of the compounds for the
active and inactive receptor conformers (Black and Shankley, 1995
;
Leff, 1995
; Milligan et al., 1995
). Thus our results suggest that it is
by stabilizing R* that the overexpressed G proteins allosterically
promote a reduction in inverse agonist binding. This hypothesis is
further supported by the fact that the inverse agonist also showed
reduced binding to the CAM
2AR.
The effect of G protein overexpression on inverse agonist binding
reflected the coupling selectivity of the
2AR
since G
s and G
i, which are both known signaling partners of this
receptor (Gilman, 1987
; Kobilka, 1992
; Crespo et al., 1995
;
Bogoyevitch et al., 1996
; Daaka et al., 1997
; Yamamoto et al.,
1997
), but not G
q, which cannot couple to
2AR (Offermanns and Simon, 1995
), promoted the
reduction in inverse agonist binding. The hypothesis that the reduction
in binding capacity resulted from the functional coupling of the
2AR to its cognate G proteins is also
supported by the effects of Gpp(NH)p. Indeed, the receptor-G protein
uncoupling promoted by the addition of the nonhydrolysable nucleotide
during the binding assay partially inhibited the effect of G protein overexpression on inverse agonist binding. Although similar effects were observed upon overexpression of G
i and G
s, no conclusion on
the relative affinity of the receptor for the two G proteins can be
drawn since no information is available on their relative level of
expression. However, the observation that both PTX and CTX led to an
increase of 125I-cyanopindolol binding capacity
in HEK293s cells expressing endogenous levels of G proteins suggests
that coupling to both Gi and Gs can occur at physiological level of G
protein expression. These result also indicate that the influences of G
protein on receptor isomerization are not limited to the insect system
but can also be seen in mammalian cells expressing normal levels of G
proteins. These results are entirely consistent with the observed
reduction in 125I-cyanopindolol binding
previously reported by Krumins et al. (1997)
upon elevation of G
s
expression using a dexamethasone-inducible promoter in S49 cells.
Although the maximal loss of inverse agonist binding observed in Sf9
cells was found upon overexpression of the G
s
1
2 complex, significant effect could also be observed when either
s or the
1
2 dimer was expressed individually. This may indicate that interaction with each of the G protein components is sufficient to
partially stabilize R*. Alternatively, association of the overexpressed mammalian subunits with their endogenous insect partners (Hepler et
al., 1993
; Butkerait et al., 1995
; Richardson and Robishaw, 1999
) may
be responsible for the effects.
The observation that G
s
1
2 overexpression could further
decrease the binding of inverse agonists to the
CAM
2AR suggests that the mutations do not
irreversibly activate the receptor but rather shift the equilibrium
toward R* and that further stabilization of the active conformer can
still be achieved upon allosteric interactions with its cognate G
proteins. This is consistent with the previous observation that inverse
agonists can inhibit the spontaneous activity of
CAM
2AR (Samama et al., 1993
; Milligan et al.,
1997
). Reduced binding capacity of
CAM
2AR when compared with
2AR was previously attributed to the greater
instability of the constitutively active mutant (Samama et al., 1993
;
Gether et al., 1997
). Although this aspect was not directly assessed in
the present study, our data suggest that the reduced ability of R* to
bind to inverse agonists may also contribute to the lower binding
generally obtained with this construct.
The allosteric effect of G protein overexpression on the binding of
inverse agonists can be considered as the mirror image of the loss of
agonist binding observed in many studies upon addition of nucleotides
that promote receptor-G protein uncoupling. However, in most cases,
such uncoupling is accompanied by a reduction of the affinity and not a
loss of binding sites for agonists (Kenakin, 1996
). Such a change in
affinity and not Bmax is in fact what the
allosteric models based on ternary complex formation predict since R*G
has a high affinity while R has a low affinity for agonists. Nevertheless, in a few cases, the nucleotide-promoted uncoupling leads
to an apparent lost in agonist binding capacity (Bouaboula et al.,
1997
; Ohtaki et al., 1998
). This could be interpreted as an indication
that the low affinity state of the receptor for the agonist is too low
for any binding to be detected under the experimental conditions used.
A similar reasoning can be applied for the apparent loss of inverse
agonist binding capacity observed in the present study following
overexpression of the G proteins. In this situation, the low affinity
state of the inverse agonists for the R*G forms of the receptor would
be undetectable. The fact that the apparent loss of binding sites
persists throughout the binding assay and that the inverse agonist is
not able to convert the entire population of receptor into the inverse
agonist-bound R form suggests that the conversion of at least a
subpopulation of the receptors is occurring at a very slow rate. This
may indicate that something is preventing the free and rapid
isomerization between R*G and R. The excess in G protein itself could
be responsible for this phenomenon as it could lock some R into the R*G
form. Given that G proteins have been shown to be in large excess of receptors in several cell types (Alousi et al., 1991
; Post et al.,
1995
; Milligan, 1996
), it may not be surprising that we observed the
phenomenon not only upon overexpression of Gi and Gs in Sf9 cells but
also in mammalian HEK293s cells expressing endogenous levels of G proteins.
Although this is the first study systematically assessing the effect of
the G protein overexpression on the direct binding properties of a
radioligand series with various inverse efficacies, changes in both
affinities and apparent Bmax linked to
alterations in the coupling state of GPCRs have previously been
reported for a few inverse agonists. For example, guanine nucleotides
treatment of membranes derived from cells expressing the human
cannabinoid receptor CB1 (Bouaboula et al., 1997
), or the
serotoninergic 5HT2C receptor (Barker et al.,
1994
; Westphal and Sanders-Bush, 1994
) was found to increase the
affinity and the number of binding sites detected by the inverse
agonists [3H]SR141716A and
[3H]mesulergine, respectively.
[3H]Spiperone binding capacity to the
5HT1A receptor was also found to be increased
upon GTP treatment (Sundaram et al., 1993
). Also, increase G
s
expression was associated with a reduction in
125I-cyanopindolol binding capacity (Krumins et
al., 1997
). More recently, overexpression of G
i1 and G
o led to a
reduction of the affinity of the inverse agonist methiothepin for the
5HT5A receptor (Francken et al., 2000
).
The good correlation between inverse efficacy and the loss of binding
promoted by G protein overexpression observed in the present study
clearly establishes that signaling efficacy and binding to specific
states (R versus R*) of the receptor are intimately linked. These
results also indicate that the ratio between R and R* is under the dual
influence of ligand binding and G protein coupling. It is therefore the
resultant of the interactions within the ternary complexes that will
ultimately determine the affinity states, the proportion of receptor in
each of the affinity states, and the signaling efficacy for a given
ligand. Whether R and R* each represent a discrete conformation or
rather collections of receptor states cannot be directly addressed
here. However, the observation that in some studies (Westphal and
Sanders-Bush, 1994
; Bouaboula et al., 1997
) guanine nucleotide can
affect simultaneously the measured affinity and the apparent
Bmax for inverse agonists suggest that more
than two conformations are involved.
Our findings should also prove to be of practical importance when using
radioligand binding assays to determine receptor number in various
pathophysiological conditions. If, as it is often the case, the
radioligands used have inverse efficacy, the conditions that modify the
R and R* ratio could be erroneously interpreted as changes in the total
receptor number. This is particularly important when considering that
many pathological conditions are accompanied by alteration in G protein
levels and thus could influence the R/R* equilibrium. For example,
increased G
s and G
i levels reported in various cardiovascular
diseases could be a contributing factor to the decrease in
AR
density often detected with radiolabeled inverse agonists in these
conditions (Schotten et al., 2000
). Although the extent to which the
allosteric effect contributed to the observed results cannot be easily
determined, the use of neutral antagonists (when available) rather than
inverse agonists as tracers may prove to be better choices.
| |
Acknowledgments |
|---|
We are grateful to Dr. Monique Lagacée and Dr. Peter Chidiac for critical reading of the manuscript.
| |
Footnotes |
|---|
Received March 29, 2001; Accepted July 20, 2001
1 Present address: Biosignal Inc., 1744 William Street, Montréal, H3J 1R4 Canada.
Supported by fellowships from the Heart and Stroke Foundation of Canada (HSFC; to M.A.), the Medical Research Council of Canada (MRCC; to G.P.), and The Canadian Hypertension Society (to H.A.) and by grants from the MRCC and the HSFC.
Dr. Michel Bouvier, Department of Biochemistry, Universitu of Montreal, 2900 Edouard Montpetit, Rm. D-360, P.O. Box 6128, Succ. Center-ville-Montreal PQ, H3C 3J7 Canada. E-mail: bouvier{at}bcm.umontreal.ca
| |
Abbreviations |
|---|
GPCRs, G protein-coupled receptors;
2AR,
2-adrenergic receptor;
CAM, constitutively activated mutant;
Sf9, Spodoptera
frugiperda 9;
G protein, guanine nucleotide-binding protein;
Gpp(NH)p, guanylylimidodiphosphate;
PBS, phosphate buffer saline;
ICI 118551, erythro-DL-1-(7-methylindan-4,1-oxy)-3-isopropylaminobutan-2-ol;
HEK, human embryonic kidney;
PTX, pertussis toxin;
CTX, cholera toxin;
FACS, fluorescence-activated cell sorter;
PAGE, polyacrylamide
gel electrophoresis;
m.o.i., multiplicity of infection.
| |
References |
|---|
|
|
|---|
2-adrenoceptor.
Nature (Lond)
374:
272-276[Medline].
-adrenergic antagonists.
Mol Pharmacol
45:
490-499[Abstract].
2-adrenergic receptor.
Mol Pharmacol
50:
662-669[Abstract].
1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function.
Proc Natl Acad Sci USA
87:
2896-2900
-adrenergic receptors on mitogen activated protein kinase.
J Biol Chem
270:
25259-25265
2-adrenergic receptor to different G proteins by protein kinase A.
Nature (Lond)
390:
88-91[Medline].
-adrenergic receptor.
J Biol Chem
255:
7108-7117
and G11
: activation of purified phospholipase C isozymes by G
subunits.
J Biol Chem
268:
14367-14375
2A-adrenoceptors.
Mol Pharmacol
53:
963-968
1B-adrenergic receptor by all amino acid substitutions at a single site.
J Biol Chem
267:
1430-1433
activation of adenylyl cyclase.
Biochem Pharmacol
54:
43-59[Medline].
1b-adrenoceptor by ligands that act as inverse agonists.
Biochem J
325:
733-739.
2-adrenergic receptor in Sf9 cells.
J Biol Chem
267:
21733-21737
15 and G
16 couple a wide variety of receptors to phospholipase C.
J Biol Chem
270:
15175-15180
2-adrenergic receptor.
J Biol Chem
268:
16483-16487
2A-adrenergic receptor discriminates between Gi heterotrimers of different 
subunit composition in Sf9 insect cell membranes.
J Biol Chem
274:
13525-13533
2-adrenergic receptor.
J Biol Chem
268:
4625-4636
-adrenergic signaling in compensated human cardiac hypertrophy depend on the underlying disease.
Am J Physiol Heart Circ Physiol
278:
2076-2083.
splice variants on
2-adrenoreceptor-mediated signaling: the
2-adrenoreceptor coupled to the long splice variant of Gs
has properties of a constitutively active receptor.
J Biol Chem
273:
5109-5116This article has been cited by other articles:
![]() |
X. J. Yao, G. Velez Ruiz, M. R. Whorton, S. G. F. Rasmussen, B. T. DeVree, X. Deupi, R. K. Sunahara, and B. Kobilka The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex PNAS, June 9, 2009; 106(23): 9501 - 9506. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Baker, I. P. Hall, and S. J. Hill Temporal Characteristics of cAMP Response Element-Mediated Gene Transcription: Requirement for Sustained cAMP Production Mol. Pharmacol., April 1, 2004; 65(4): 986 - 998. [Abstract] [Full Text] |
||||
![]() |
T. Kenakin Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Baker, I. P. Hall, and S. J. Hill Agonist and Inverse Agonist Actions of {beta}-Blockers at the Human {beta}2-Adrenoceptor Provide Evidence for Agonist-Directed Signaling Mol. Pharmacol., December 1, 2003; 64(6): 1357 - 1369. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||